Practitioners received insight into treating patients across the GI field—colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer, neuroendocrine tumors (NETs), gastric cancer, and sarcomas—during the GI cancers track at the 2016 Chemotherapy Foundation Symposium.
Two major developments in oncology—the dramatic success of some immunotherapies and targeted drugs and an equally dramatic rise in the cost of care—have created policy issues, more serious than ever, regarding access to care.
Progress has been too slow for patients with gastrointestinal cancers,” says Craig Lustig, associate director of the Ruesch Center for the Cure of GI Cancers. Part of Georgetown Lombardi Comprehensive Cancer Center, the Ruesch Center became founding member and academic center for the new GI Cancers Alliance.
The unprecedented understanding of cancer as a series of complex diseases holds the promise of new, more effective therapies for GI cancer patients, and indeed all cancer patients. The briefing examined the rapid advances in science around cancer, increasing costs and clinical value of new discoveries and creating a balance that ensures patient access.
In an interview with Targeted Oncology, John L. Marshall, MD, chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, clinical research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the new research into GI molecular subtyping, targeted therapies for the malignancy, and identifying new patients.
The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center hosts its 2016 Cancer Policy Briefing, Wednesday, September 14 from 9:00 to 11:30 a.m. at the Georgetown University Law Center.
John L. Marshall, MD with Dirk Arnold, MD, Zorana Maravic, BSc; Michael A. Sapienza, and Eden Stotsky-Himelfarb, BSN, RN discuss how to close gaps in communication that hinder optimal management of patients with metastatic colorectal cancer (mCRC).
So, if you’re like most, these new medicines are new to you. And you can look them up online, you can figure out how to deal with them by asking friends and neighbors. But, really, until you’ve tried it, until you’ve used it, it doesn’t really click.
In an interview with OncLive, Dr. John Marshall discusses second-line treatment options for patients with mCRC, along with who is most appropriate to receive regorafenib and how to manage doses and toxicities when using the multikinase inhibitor.
“When I went to medical school, I was taught that colon cancer is a 50 and older disease, but on any given day more than half of my clinic is filled with patients under the age of 50,” said Dr. John Marshall